IART combines a perfect earnings-beat streak and cheap valuation with limited remaining upside near its 52-week high, a leverage penalty, weak momentum, and elevated bearish options positioning, netting out to reducing rather than adding to the position.
Thesis pillars
- Perfect Earnings Beat Streak→Stable
- Attractive Valuation Cheap Multiples→Stable
- Limited Upside Near 52 Week High→Stable
- +2 more pillars — see the Why tab for full reasoning
Integra LifeSciences Holdings C (IART) Stock Analysis
Catalyst-Driven edge
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $17.30, but acceptable to hold if already in. Reasons: Concentration risk — Product: CSS segment (70.0%); Analyst target reached - limited upside remaining.
Integra LifeSciences is a global medical technology company selling neurosurgery, ENT, and specialty surgical instruments through its Codman Specialty Surgical segment (about 70% of revenue) and regenerative wound-care and private-label products through its Tissue Technologies... Read more
Hold if already holding. Not a fresh buy at $17.30, but acceptable to hold if already in. Reasons: Concentration risk — Product: CSS segment (70.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.6/10, moderate confidence.
Passes 4/7 gates (clean insider activity, earnings proximity 22d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
About Integra LifeSciences Holdings C
About Integra LifeSciences Holdings C
Integra LifeSciences splits its business into two segments: Codman Specialty Surgical, roughly 70% of total revenue, covering neurosurgery, neurocritical care, and ENT instrumentation, and Tissue Technologies, about 30%, focused on wound reconstruction, regenerative scaffolds, and private-label manufacturing. The company operates manufacturing and research sites across California, Massachusetts, New Jersey, Puerto Rico, France, Germany, Ireland, Israel, and Switzerland, and in 2025 no single customer accounted for more than 10% of consolidated revenue.
Integra sells its neurosurgical devices, surgical instruments, and regenerative tissue products through a combination of direct sales representatives organized by physician specialty and independent distributors serving hospitals, integrated health networks, group purchasing organizations, and surgery centers globally. Demand ties to hospital capital budgets and elective-procedure volume, with fourth-quarter revenue typically the strongest as hospitals spend down annual budgets. Raw materials such as bovine collagen, porcine urinary bladder matrix, and Manuka honey feed the Tissue Technologies platform, while certain components and raw materials are available only from one or a limited number of suppliers, a risk the company manages through long-term supply contracts and buffer inventory. On the pipeline side, Integra is pursuing FDA premarket approval for SurgiMend in post-mastectomy breast reconstruction and for DuraSorb in implant-based breast reconstruction, both targeted for 2026, following a 510(k) clearance for the Aurora Surgiscope cranial retractor system earlier in 2025. Competitors include divisions of Medtronic, Stryker, and Smith & Nephew.
Show full overview
Integra's clearest near-term risk lens is regulatory and quality-system exposure: the FDA's new Quality Management System Regulation took effect February 2, 2026, replacing the prior Quality System Regulation just as the company executes a multi-year Compliance Master Plan to remediate quality-system gaps identified across its manufacturing network. That backdrop helps explain the $511.4 million goodwill impairment Integra recorded in the second quarter of 2025 across its Tissue Technologies, Neurosurgery, and Instruments and ENT units, a charge management tied to tariff-driven share-price declines alongside quality and operational issues. With PMA approval for SurgiMend still pending the operationalization of a new Braintree, Massachusetts facility expected in 2026, further manufacturing or compliance delays could push that approval timeline out again.
See also: Healthcare · Medical Devices
From Integra LifeSciences Holdings C's most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Integra LifeSciences Holdings C
Latest news
- NEWS Citigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $19 — benzinga Jul 8, 2026 positive
Generated 2026-07-08T21:03:53Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCSS segment70%10-K Item 1: 'The CSS segment, which represents approximately 70% of our total revenue, consists of market-leading technologies'
- MEDIUMSupplierlimited number of suppliers10-K Item 1: 'certain components and raw materials are available only from one or a limited number of suppliers'
Material Events(8-K, last 90d)
- 2026-05-08Item 5.02LOWAt Integra's May 7, 2026 Annual Meeting, stockholders approved Amendment No. 3 to the 2003 Equity Incentive Plan, increasing shares available for awards by 3,550,000. Routine governance matter; no executive changes disclosed in this filing.SEC filing →
- 2026-05-05Item 5.02MEDIUMMojdeh Poul departed as President and CEO effective April 30, 2026. Dr. Stuart Essig, the company's Chairman and CEO from 1997-2012, succeeded her effective May 1, 2026, providing an immediate clean handoff. No reason cited for Poul's departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $17.30, but acceptable to hold if already in. Reasons: Concentration risk — Product: CSS segment (70.0%); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $18.54 (+7.2%), stop $16.25 (−6.5%), A.R:R -1.4:1. Score 5.6/10, moderate confidence.
Take-profit target: $18.54 (+7.2% upside). Target $18.54 (+7.2%), stop $16.25 (−6.5%), A.R:R -1.4:1. Stop-loss: $16.25.
Concentration risk — Product: CSS segment (70.0%); Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.0): -1.0.
Integra LifeSciences Holdings C trades at a P/E of N/A (forward 6.9). TrendMatrix value score: 7.6/10. Verdict: Hold.
16 analysts cover IART with a consensus score of 3.6/5. Average price target: $17.
What does Integra LifeSciences Holdings C do?Integra LifeSciences is a global medical technology company selling neurosurgery, ENT, and specialty surgical...
Integra LifeSciences is a global medical technology company selling neurosurgery, ENT, and specialty surgical instruments through its Codman Specialty Surgical segment (about 70% of revenue) and regenerative wound-care and private-label products through its Tissue Technologies segment (about 30%). The company manufactures medical devices at facilities across the U.S., Puerto Rico, France, Germany, Ireland, Israel and Switzerland, selling through direct sales forces and distributors to hospitals and surgery centers worldwide, with no single customer exceeding 10% of 2025 revenue.